Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

This study is testing whether ivosidenib — a targeted oral drug that blocks a mutated enzyme called IDH1 — taken after surgery and standard chemotherapy can prevent bile duct cancer (cholangiocarcinoma) from coming back in patients whose tumors were successfully removed. **You may be eligible if...** - You are 18 or older - You have been diagnosed with intrahepatic cholangiocarcinoma (bile duct cancer inside the liver) that was completely removed with surgery (R0 resection), with no spread to other organs - Your tumor has a confirmed IDH1 mutation - You have completed or are finishing standard post-surgery chemotherapy **You may NOT be eligible if...** - Your tumor does not have the IDH1 mutation - Your cancer has spread to other parts of the body - Surgery did not fully remove the tumor - You have significant liver, heart, or other organ problems Talk to your doctor to see if this trial is right for you.